Does the media refer more to CLDX or HALO?

In the previous week, Halozyme Therapeutics had 11 more articles in the media than Celldex Therapeutics. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 2 mentions for Celldex Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.38 beat Celldex Therapeutics' score of 1.31 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Halozyme Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RGEN or CLDX?

In the previous week, Repligen had 3 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Repligen and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat Repligen's score of 0.60 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALKS or CLDX?

In the previous week, Alkermes had 3 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Alkermes and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat Alkermes' score of 1.29 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LGND or CLDX?

In the previous week, Ligand Pharmaceuticals had 6 more articles in the media than Celldex Therapeutics. MarketBeat recorded 8 mentions for Ligand Pharmaceuticals and 2 mentions for Celldex Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 1.34 beat Celldex Therapeutics' score of 1.31 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BCRX or CLDX?

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 4 mentions for BioCryst Pharmaceuticals and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat BioCryst Pharmaceuticals' score of 0.91 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Celldex Therapeutics (CLDX) Competitors

$31.43 0.00 (0.00%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$32.17 +0.74 (+2.35%)

As of 04:48 AM Eastern

Compare

CLDX vs. HALO, RGEN, ALKS, LGND, and BCRX

Should you buy Celldex Therapeutics stock or one of its competitors? MarketBeat compares Celldex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Celldex Therapeutics include Halozyme Therapeutics (HALO), Repligen (RGEN), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "biotechnology" industry.

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

In the previous week, Halozyme Therapeutics had 11 more articles in the media than Celldex Therapeutics. MarketBeat recorded 13 mentions for Halozyme Therapeutics and 2 mentions for Celldex Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.38 beat Celldex Therapeutics' score of 1.31 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Halozyme Therapeutics	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Halozyme Therapeutics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,601.91	-$258.76M	-$4.26	N/A
Halozyme Therapeutics	$1.40B	5.65	$316.89M	$2.78	23.94

Celldex Therapeutics currently has a consensus target price of $49.78, indicating a potential upside of 58.38%. Halozyme Therapeutics has a consensus target price of $80.67, indicating a potential upside of 21.23%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Celldex Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

97.8% of Halozyme Therapeutics shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Halozyme Therapeutics has a net margin of 23.13% compared to Celldex Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 187.91% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Halozyme Therapeutics	23.13%	187.91%	21.92%

Celldex Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Summary

Halozyme Therapeutics beats Celldex Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to Repligen?

Repligen (NASDAQ:RGEN) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Repligen currently has a consensus price target of $166.15, indicating a potential upside of 34.05%. Celldex Therapeutics has a consensus price target of $49.78, indicating a potential upside of 58.38%. Given Celldex Therapeutics' higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Repligen had 3 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Repligen and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat Repligen's score of 0.60 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.6% of Repligen shares are owned by institutional investors. 0.6% of Repligen shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Repligen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	9.47	$48.89M	$0.90	137.72
Celldex Therapeutics	$1.54M	1,601.91	-$258.76M	-$4.26	N/A

Repligen has a beta of 1.09, suggesting that its stock price is 9% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Repligen has a net margin of 6.73% compared to Celldex Therapeutics' net margin of 0.00%. Repligen's return on equity of 4.88% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	6.73%	4.88%	3.48%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Summary

Repligen beats Celldex Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

In the previous week, Alkermes had 3 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for Alkermes and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat Alkermes' score of 1.29 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.76	$241.66M	$0.90	46.88
Celldex Therapeutics	$1.54M	1,601.91	-$258.76M	-$4.26	N/A

Alkermes presently has a consensus target price of $45.40, indicating a potential upside of 7.61%. Celldex Therapeutics has a consensus target price of $49.78, indicating a potential upside of 58.38%. Given Celldex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Celldex Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

95.2% of Alkermes shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alkermes has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Alkermes has a net margin of 9.78% compared to Celldex Therapeutics' net margin of 0.00%. Alkermes' return on equity of 9.26% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Summary

Alkermes beats Celldex Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Ligand Pharmaceuticals has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

Ligand Pharmaceuticals has a net margin of 55.95% compared to Celldex Therapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 16.19% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
Celldex Therapeutics	N/A	-50.72%	-46.59%

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Ligand Pharmaceuticals had 6 more articles in the media than Celldex Therapeutics. MarketBeat recorded 8 mentions for Ligand Pharmaceuticals and 2 mentions for Celldex Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 1.34 beat Celldex Therapeutics' score of 1.31 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ligand Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	17.34	$124.45M	$7.37	31.47
Celldex Therapeutics	$1.54M	1,601.91	-$258.76M	-$4.26	N/A

Ligand Pharmaceuticals currently has a consensus price target of $257.71, indicating a potential upside of 11.10%. Celldex Therapeutics has a consensus price target of $49.78, indicating a potential upside of 58.38%. Given Celldex Therapeutics' higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Ligand Pharmaceuticals beats Celldex Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

BioCryst Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioCryst Pharmaceuticals	$874.84M	2.59	$263.86M	-$1.78	N/A
Celldex Therapeutics	$1.54M	1,601.91	-$258.76M	-$4.26	N/A

85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Celldex Therapeutics has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -51.71%. Celldex Therapeutics' return on equity of -50.72% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%
Celldex Therapeutics	N/A	-50.72%	-46.59%

BioCryst Pharmaceuticals presently has a consensus target price of $20.70, indicating a potential upside of 132.32%. Celldex Therapeutics has a consensus target price of $49.78, indicating a potential upside of 58.38%. Given BioCryst Pharmaceuticals' higher probable upside, research analysts plainly believe BioCryst Pharmaceuticals is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioCryst Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.75
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Celldex Therapeutics. MarketBeat recorded 4 mentions for BioCryst Pharmaceuticals and 2 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.31 beat BioCryst Pharmaceuticals' score of 0.91 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioCryst Pharmaceuticals beats Celldex Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Celldex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLDX vs. The Competition

Export

Metric	Celldex Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.47B	$3.40B	$6.40B	$12.57B
Dividend Yield	N/A	2.29%	2.68%	5.31%
P/E Ratio	-7.38	18.88	21.59	26.27
Price / Sales	1,601.91	334.85	555.66	114.93
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	3.96	6.93	10.07	6.86
Net Income	-$258.76M	$24.20M	$3.56B	$337.26M
7 Day Performance	2.28%	4.11%	2.84%	3.58%
1 Month Performance	N/A	N/A	N/A	-0.79%
1 Year Performance	61.26%	66.00%	37.64%	39.67%

Celldex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLDX Celldex Therapeutics	2.4287 of 5 stars	$31.43 flat	$49.78 +58.4%	+61.3%	$2.47B	$1.54M	N/A	150
HALO Halozyme Therapeutics	4.6531 of 5 stars	$68.32 flat	$80.67 +18.1%	+18.9%	$8.10B	$1.40B	24.58	390	Positive News Gap Up
RGEN Repligen	3.899 of 5 stars	$115.06 flat	$166.15 +44.4%	+5.3%	$6.49B	$738.26M	127.85	2,000
ALKS Alkermes	2.6293 of 5 stars	$36.80 flat	$45.40 +23.4%	+36.8%	$6.13B	$1.48B	40.89	2,050	Positive News Gap Down
LGND Ligand Pharmaceuticals	3.4904 of 5 stars	$229.33 flat	$257.71 +12.4%	+124.8%	$4.60B	$268.09M	31.12	80	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLDX) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celldex Therapeutics (CLDX) Competitors

CLDX vs. HALO, RGEN, ALKS, LGND, and BCRX

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Summary

How does Celldex Therapeutics compare to Repligen?

Summary

How does Celldex Therapeutics compare to Alkermes?

Summary

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Summary

How does Celldex Therapeutics compare to BioCryst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celldex Therapeutics (CLDX) Competitors

CLDX vs. HALO, RGEN, ALKS, LGND, and BCRX

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Does the media refer more to CLDX or HALO?

Which has stronger earnings & valuation, CLDX or HALO?

Do analysts rate CLDX or HALO?

Do institutionals & insiders hold more shares of CLDX or HALO?

Is CLDX or HALO more profitable?

Which has more risk & volatility, CLDX or HALO?

Summary

How does Celldex Therapeutics compare to Repligen?

Do analysts prefer RGEN or CLDX?

Does the media prefer RGEN or CLDX?

Do institutionals and insiders believe in RGEN or CLDX?

Which has better earnings & valuation, RGEN or CLDX?

Which has more volatility and risk, RGEN or CLDX?

Is RGEN or CLDX more profitable?

Summary

How does Celldex Therapeutics compare to Alkermes?

Does the media prefer ALKS or CLDX?

Which has preferable valuation & earnings, ALKS or CLDX?

Do analysts prefer ALKS or CLDX?

Do insiders and institutionals believe in ALKS or CLDX?

Which has more risk & volatility, ALKS or CLDX?

Is ALKS or CLDX more profitable?

Summary

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Which has more risk and volatility, LGND or CLDX?

Is LGND or CLDX more profitable?

Do insiders & institutionals believe in LGND or CLDX?

Does the media favor LGND or CLDX?

Which has stronger earnings and valuation, LGND or CLDX?

Do analysts prefer LGND or CLDX?

Summary

How does Celldex Therapeutics compare to BioCryst Pharmaceuticals?

Which has better valuation and earnings, BCRX or CLDX?

Do institutionals and insiders believe in BCRX or CLDX?

Is BCRX or CLDX more profitable?

Do analysts prefer BCRX or CLDX?

Which has more volatility and risk, BCRX or CLDX?

Does the media favor BCRX or CLDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools